Nps Pharmaceuticals, Inc.

Lance G Hammerland

Thomas M Stormann

Forrest H Fuller

Karen J Krapcho

Rachel T Simin

Laura L Storjohann

Cynthia Levinthal

James E Garrett

James G Busby

The present invention features G-protein fusion receptors and chimeric GABAreceptors (GABARs), nucleic acid encoding such receptors, and the use of such receptors and nucleic acid. G-protein fusion receptors comprise at least one domain from a CaR, an mGluR, and/or a GABAreceptor fused directly or through a linker to a guanine nucleotide-binding protein (G-protein). Chimeric GABARs comprise at least one of a GABAR extracellular domain, a GABAR transmembrane domain, or a GABAR intracellular domain and one or more domains from a mGluR subtype 8 (mGluR8) and/or a CaR.

G-protein fusion receptors and constructs encoding same

A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR, as well as compounds that modulate mGluR activity, may be used in the diagnosis and treatment of neurological disorders and diseases.

Human metabotropic glutamate receptor

A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR as well as compounds that modulate mGluR activity may be used in the diagnosis and treatment of neurological disorders and diseases.

Nucleic acids encoding mGLuR/CaR chimera

A human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR as well as compounds that modulate mGluR activity may be used in the diagnosis and treatment of neurological disorders and diseases.

Isolated human metabotropic glutamate receptor Mglur-8

The present invention provides chimeric receptors. The chimeric receptors comprise at least one region homologous to a region of a metabotropic glutamate receptor and at least one region homologous to a region of a calcium receptor. The invention also includes methods of preparing such chimeric receptors, and methods of using such receptors to identify and characterize compounds which modulate the activity of metabotropic glutamate receptors or calcium receptors. The invention also relates to compounds and methods for modulating metabotropic glutamate receptor activity and binding to metabotropic glutamate receptors. Modulation of metabotropic glutamate receptor activity can be used for different purposes such as treating neurological disorders and diseases, inducing an analgesic effect, cognition enhancement, and inducing a muscle-relaxant effect.

Growing community of inventors

Salt Lake City, UT, United States of America

Lance G Hammerland